Elite Pharmaceuticals Inc (ELTP)

[Hike]

There clearly is a trend toward abuse deterrent opioids, especially following the FDA's decision to Purdue's Citizens Petition to not approve non-abuse deterrent generic versions of OxyContin when Purdue's patent expired in April 2013.

The FDA also did not agree with Endo's Citizen's Petition to block non-abuse deterrent generics of Opana as the FDA did not believe Endo's abuse deterrent product was less abusable than the original formulation after looking at the mechanics of the technology as well as post-marketing experiences.

I believe the key takaway from these events are there is growing pressure to thwart the abuse and misuse of prescription painkillers, but the FDA is also clearly looking at the underlying technology of abuse deterrent formulations.

Contact:

For Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations, 518-398-6222

[e-mail]

www.elitepharma.com




If you no longer wish to receive communications from Elite Pharmaceuticals, please click here.

3 Attachments
PDF
Mfg Under Pressure to Manage Painkillers.pdf
PDF
STOPP Act press release from Congressman Keatings office.pdf
PDF
Upton-Coburn Congressional Ltr to FDA.pdf